Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective α7 nicotinic acetylcholine receptor agonist strategy

Stephen I. Deutsch; Richard B. Rosse; Barbara L. Schwartz; Nina R. Schooler; Brooke L. Gaskins; Katrice D. Long; John Mastropaolo

doi:10.1016/j.euroneuro.2007.05.008

Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective α₇ nicotinic acetylcholine receptor agonist strategy

Stephen I. Deutsch
, Richard B. Rosse
, Barbara L. Schwartz
, Nina R. Schooler
, Brooke L. Gaskins
, Katrice D. Long
, John Mastropaolo

Psychiatry

SUNY Downstate Health Sciences University

Department of Veterans Affairs
Georgetown University

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

The regionally selective reduction of expression of the α₇ nicotinic acetylcholine receptor (α₇ nAChR) in schizophrenia underlies impaired sensory inhibition, a possible endophenotype of the disorder. This ligand-gated ion channel receptor has been proposed as a pharmacotherapeutic target in schizophrenia. The current study examined the effect of CDP-choline alone and the combination of CDP-choline and galantamine, administered acutely and once-daily for five consecutive days, in an animal model of NMDA receptor hypofunction that is relevant to schizophrenia. The results support the allosteric modulatory influence of galantamine on CDP-choline; however, individual doses of CDP-choline and galantamine must be carefully titrated in order to achieve optimal levels of α₇ nAChR "agonism" that may be necessary for the desired therapeutic effect.

Original language	English
Pages (from-to)	147-151
Number of pages	5
Journal	European Neuropsychopharmacology
Volume	18
Issue number	2
DOIs	https://doi.org/10.1016/j.euroneuro.2007.05.008
State	Published - Feb 2008

Keywords

CDP-choline
Galantamine
NMDA receptor
Schizophrenia
α nicotinic acetylcholine receptor

Access to Document

10.1016/j.euroneuro.2007.05.008

Cite this

Deutsch, S. I., Rosse, R. B., Schwartz, B. L., Schooler, N. R., Gaskins, B. L., Long, K. D., & Mastropaolo, J. (2008). Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective α₇ nicotinic acetylcholine receptor agonist strategy. European Neuropsychopharmacology, 18(2), 147-151. https://doi.org/10.1016/j.euroneuro.2007.05.008

@article{791df2e01da34ce0857f524a5812a062,

title = "Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective α7 nicotinic acetylcholine receptor agonist strategy",

abstract = "The regionally selective reduction of expression of the α7 nicotinic acetylcholine receptor (α7 nAChR) in schizophrenia underlies impaired sensory inhibition, a possible endophenotype of the disorder. This ligand-gated ion channel receptor has been proposed as a pharmacotherapeutic target in schizophrenia. The current study examined the effect of CDP-choline alone and the combination of CDP-choline and galantamine, administered acutely and once-daily for five consecutive days, in an animal model of NMDA receptor hypofunction that is relevant to schizophrenia. The results support the allosteric modulatory influence of galantamine on CDP-choline; however, individual doses of CDP-choline and galantamine must be carefully titrated in order to achieve optimal levels of α7 nAChR {"}agonism{"} that may be necessary for the desired therapeutic effect.",

keywords = "CDP-choline, Galantamine, NMDA receptor, Schizophrenia, α nicotinic acetylcholine receptor",

author = "Deutsch, \{Stephen I.\} and Rosse, \{Richard B.\} and Schwartz, \{Barbara L.\} and Schooler, \{Nina R.\} and Gaskins, \{Brooke L.\} and Long, \{Katrice D.\} and John Mastropaolo",

year = "2008",

month = feb,

doi = "10.1016/j.euroneuro.2007.05.008",

language = "English",

volume = "18",

pages = "147--151",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier B.V.",

number = "2",

}

Deutsch, SI, Rosse, RB, Schwartz, BL, Schooler, NR, Gaskins, BL, Long, KD & Mastropaolo, J 2008, 'Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective α₇ nicotinic acetylcholine receptor agonist strategy', European Neuropsychopharmacology, vol. 18, no. 2, pp. 147-151. https://doi.org/10.1016/j.euroneuro.2007.05.008

Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective α₇ nicotinic acetylcholine receptor agonist strategy. / Deutsch, Stephen I.; Rosse, Richard B.; Schwartz, Barbara L. et al.
In: European Neuropsychopharmacology, Vol. 18, No. 2, 02.2008, p. 147-151.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia

T2 - Development of a selective α7 nicotinic acetylcholine receptor agonist strategy

AU - Deutsch, Stephen I.

AU - Rosse, Richard B.

AU - Schwartz, Barbara L.

AU - Schooler, Nina R.

AU - Gaskins, Brooke L.

AU - Long, Katrice D.

AU - Mastropaolo, John

PY - 2008/2

Y1 - 2008/2

N2 - The regionally selective reduction of expression of the α7 nicotinic acetylcholine receptor (α7 nAChR) in schizophrenia underlies impaired sensory inhibition, a possible endophenotype of the disorder. This ligand-gated ion channel receptor has been proposed as a pharmacotherapeutic target in schizophrenia. The current study examined the effect of CDP-choline alone and the combination of CDP-choline and galantamine, administered acutely and once-daily for five consecutive days, in an animal model of NMDA receptor hypofunction that is relevant to schizophrenia. The results support the allosteric modulatory influence of galantamine on CDP-choline; however, individual doses of CDP-choline and galantamine must be carefully titrated in order to achieve optimal levels of α7 nAChR "agonism" that may be necessary for the desired therapeutic effect.

AB - The regionally selective reduction of expression of the α7 nicotinic acetylcholine receptor (α7 nAChR) in schizophrenia underlies impaired sensory inhibition, a possible endophenotype of the disorder. This ligand-gated ion channel receptor has been proposed as a pharmacotherapeutic target in schizophrenia. The current study examined the effect of CDP-choline alone and the combination of CDP-choline and galantamine, administered acutely and once-daily for five consecutive days, in an animal model of NMDA receptor hypofunction that is relevant to schizophrenia. The results support the allosteric modulatory influence of galantamine on CDP-choline; however, individual doses of CDP-choline and galantamine must be carefully titrated in order to achieve optimal levels of α7 nAChR "agonism" that may be necessary for the desired therapeutic effect.

KW - CDP-choline

KW - Galantamine

KW - NMDA receptor

KW - Schizophrenia

KW - α nicotinic acetylcholine receptor

UR - https://www.scopus.com/pages/publications/37349010356

U2 - 10.1016/j.euroneuro.2007.05.008

DO - 10.1016/j.euroneuro.2007.05.008

M3 - Article

C2 - 17656074

SN - 0924-977X

VL - 18

SP - 147

EP - 151

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

IS - 2

ER -

Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective α₇ nicotinic acetylcholine receptor agonist strategy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this